2016
DOI: 10.17148/iarjset.2016.32
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: Genetic engineering technologies allow mass production of proteins for a variety of applications mainly in the biopharmaceutical industry. FcγRIIa (CD32a) and FcγRIIIa (CD16a) are antibodies cell surface receptors that mediate important immune functions. Fcγ receptors are currently the focus in developing novel therapeutic antibodies. Herein, we report the production at a high yields of genetically engineered soluble forms of the extracellular domain of the main genetic variants of CD16a (158F/V) (1.5mg/ml, 0.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 26 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?